AR and posterior cortical atrophy: However, some studies have reported that there are many problems with the direct or indirect methods associated with the resistance to AR-targeted therapies in PCa because of amplification or overexpression of AR, ligand-binding domain mutations, ligand-independent activation, and the expression of active AR splice variants.